Haploidentical Bone Marrow Transplantation in Primary Immune Deficiency: Stem Cell Selection and Manipulation
Section snippets
T cell depleted stem cell transplantation
Stem cell transplantation offers a curative treatment for many patients with a severe form of immune deficiency, as well as malignant and nonmalignant hematologic disorders. As an identical, related, stem cell donor is available only in a small minority of cases (15%–20%),7 alternative donors are needed. The 2 alternative options are allogeneic stem cell transplantation from an unrelated identical donor and haploidentical related donor (in which the donor and recipient share only 1 of 2
Methods of TCD
Three major TCD methods have been used successfully for the treatment of PID patients.
Long-term survival after TCD HSCT
A review of the literature regarding the long-term results of T cell depleted stem cell transplantation reveals an unexpected variability in the outcome and survival of patients treated. Some of the disparity could result from the nature of the primary disease but other variables should be considered, such as supportive care, the degree of TCD, pretreatment conditioning regimen (CR) and posttransplantation prophylaxis.
GVHD and TCD HSCT
TCD was developed as a method to prevent GVHD when using haploidentical stem cell grafts. The prevention of GVHD is of great importance as retrospective analysis has shown it is a significant risk factor for reduced survival when appearing either in the early form of aGVHD or when present 6 months after transplantation in the form of cGVHD.37, 40
In addition, as was recently suggested, GVHD might impair thymic function and affect long-term T cell immune reconstitution.47, 48 Despite the initial
Engraftment
In the first series of TCD HSCT in SCID patients the problem of early graft rejection, which could be corrected by a second transplant from the other parent, was observed. In the initial work of Reisner and colleagues20 from 1983, all 3 patients who underwent TCD HSCT required repeat stem cell grafts as a result of early graft rejection. Several subsequent studies in which the rate of early graft rejection reached up to 30% and necessitated repeated transplantation confirmed these results.2, 38
Methods to enhance recovery following TCD HSCT
The delayed T cell reconstitution following TCD HSCT is a major clinical problem as it is a period of profound immune deficiency during which the patient is exposed to lethal infectious complication. Several modalities have been suggested in an attempt to shorten the period of risk.
Haploidentical TCD HSCT in the neonatal period improved overall survival rate (95%) and might shorten the period between HSCT and normal T cell function.42 Early CD34+ stem cell boost as a means to correct incomplete
Summary
Several primary immune deficiency diseases can be cured by allogeneic HSCT. In the more severe form of otherwise lethal SCID disease, with the exception of experimental gene therapy, HSCT is the only curative treatment. It is well established that HSCT from an identical related donor offers the best survival outcome, lowest GVHD rate, and to some extent improved immune reconstitution. However, as a matched sibling donor is available for only a few patients, and because SCID is a medical
References (75)
- et al.
The International Union of Immunological Societies (IUIS) primary immunodeficiency diseases (PID) classification committee
J Allergy Clin Immunol
(2007) Primary immunodeficiency diseases: an experimental model for molecular medicine
Lancet
(2001)- et al.
Immunological reconstitution of sex-linked lymphopenic immunological deficiency
Lancet
(1968) - et al.
Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells
Lancet
(1981) - et al.
Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs
J Allergy Clin Immunol
(2008) - et al.
Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin
Cell Immunol
(1976) - et al.
Use of soybean agglutinin for the separation of mouse B and T lymphocytes
Biochem Biophys Res Commun
(1976) - et al.
Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin
Lancet
(1980) - et al.
Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells
Blood
(1983) - et al.
Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow
Lancet
(1984)
HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine
Blood
Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation
Lancet
Failure of a pan-reactive anti-T cell antibody, OKT 3, to prevent graft versus host disease in severe combined immunodeficiency
J Pediatr
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement
Blood
Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
Blood
Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency
J Allergy Clin Immunol
Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients
Blood
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99
Lancet
Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival
Blood
Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency
J Pediatr
Management options for adenosine deaminase deficiency. Proceedings of the EBMT satellite workshop (Hamburg, March 2006)
Clin Immunol
Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation
Blood
Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program
Blood
Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases
Biol Blood Marrow Transplant
Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress
Curr Opin Immunol
Detection of maternal DNA in placental/umbilical cord blood by locus-specific amplification of the noninherited maternal HLA gene
Blood
Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency
Blood
T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny
Blood
Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants
Blood
Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts
Blood
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions
Blood
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation
Blood
Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation
Blood
Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations
Blood
T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events
Blood
Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency
Blood
Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype
Blood
Cited by (0)
A version of this article was previously published in the Immunology and Allergy Clinics of North America, 30:1.